Uncategorised - European Medical Journal

Meet the expert: Managing Axial Psoriatic Arthritis

In this short summary video, Prof. Mease discusses the need for consensus on the definition and classification criteria for the axial manifestation of PsA, also highlighting the need for specific clinical assessments and clinical trials designed to investigate the efficacy of therapy options in this patient population.

LEO Pharma’s Monica Shaw on access to medicine challenges

Monica Shaw, Executive Vice President, Region EUROPE Plus, LEO Pharma, speaks with GOLD about digital transformation in healthcare

A New Prognosis for Multiple Sclerosis

We explore Professor Leigh Charvet’s vast research within multiple sclerosis, consider her time working in industry compared with her experiences in…

EMJ Podcast: Spotlight on Non-Small Cell Lung Cancer (NSCLC)

In this episode, Dr Marina Garassino explores the unmet needs for patients living with EGFR-mutated non-small cell lung cancer (NSCLC).

Medac Feature Image

Medac Satellite Symposium Eular 2021: MTX in RA therapy

Methotrexate has been established beyond doubt as the primary disease-modifying drug for the therapy of rheumatoid arthritis.

EMJ Podcast: Latest Developments in RET-driven Thyroid Cancer

Hear from two experts, as they discuss the latest efficacy and safety data in patients with RET-driven thyroid cancer, RET testing, and the future of RET-driven diseases.

Talking to Vanessa Pott

Vanessa Pott, Director, Global Patient Insights and Advocacy, Merck KGaA, discusses patient advocacy and supporting carers.

Neph 9.1 Content Image

Review of the European Renal Association–European Dialysis and Transplant Association (ERA-EDTA) Virtual Congress 2021

BERLIN, the modern architectural capital city of Germany hosted this year’s ERA-EDTA Virtual Congress that took place on 5-8th June 2021.

Secondary Hyperparathyroidism in Non dialysis Chronic Kidney Disease

Secondary Hyperparathyroidism in Non-dialysis Chronic Kidney Disease

Chronic kidney disease can result in morbidity and mortality not only due to renal dysfunction itself, but also to associated…

Neph 9.1 Content Image

Nephrotoxic Mechanisms of Gadolinium: Implications for the Use of Gadolinium-Based Contrast Agents

Gadolinium-based contrast agents are widely used for MRI. Although they may be considered well-tolerated at recommended dosing levels, recent evidence supports the deposition of free gadolinium in the tissues and its slow release into circulation, resulting in long-term toxicity, which is aggravated in renal patients.